Overview

To Evaluate the Effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the effect of Gemfibrozil on the Pharmacokinetics and Pharmacodynamics of a Single Dose of AZD1656
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Gemfibrozil
Criteria
Inclusion Criteria:

- Patients with confirmed Type 2 diabetes mellitus for at least 1 year and treated with
metformin.

- Body mass index between ≥19 and ≤42 kg/m2.

Exclusion Criteria:

- Intake of another investigational drug within the last 30 days prior to enrolment.

- Clinically significant illness or clinically relevant trauma.